

# **QIBA Overview**

The Quantitative Imaging Biomarkers Alliance (*QIBA*) was organized by RSNA in 2007 to unite researchers, healthcare professionals, and industry stakeholders in the advancement of quantitative imaging and the use of biomarkers in clinical trials and practice.

### Definition

Quantitative imaging is the acquisition, extraction and characterization of relevant quantifiable features from medical images for use in research and patient care. Standardizing the use of imaging biomarkers in clinical trials will reduce the variance inherent across different hardware and software platforms. RSNA views this work as a step toward an ultimate goal of enhancing the use of quantitative imaging methods in clinical practice.

QIBA is an important part of RSNA's commitment to transforming radiology from a *qualitative* to a more *quantitative* science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.

### **QIBA Mission**

Improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, patients and time.

The work of QIBA has advanced through the generous efforts of volunteer members from academia, the medical device industry, the pharmaceutical and other business sectors, and government. There are 18 biomarker committees open to all interested persons. These Committees have specific tasks and deliverables for their respective modalities and disease-based approach:

CT Angiography	Magnetic Resonance Elastography (MRE)
CT Small Lung Nodule	Musculoskeletal (MSK)
CT Volumetry	Proton Density Fat Fraction (PDFF)
Lung Density	FDG-PET/CT
Arterial Spin Labeling (ASL) [EIBIR]	PET-Amyloid
DCE-MRI	SPECT I-123
DSC-MRI	SPECT Tc 99m
DTI+ MRI	Ultrasound Shear Wave Speed (US-SWS)
DWI-MRI	Ultrasound Volume Blood Flow (US-VBF) [AIUM]
Functional magnetic resonance imaging (fMRI)	Contrast Enhanced Ultrasound (CEUS)

### The QIBA Approach

The work of the QIBA Committees follows a defined, coordinated process to develop solutions and promote their adoption.

**I.** *Identify Sources of Error and Variation in Quantitative Results from Imaging Methods:* Stakeholders work to identify problems leading to error or variability in quantitative results from imaging methods.

**II.** *Specify Potential Solutions:* Stakeholders identify potential strategies and infrastructure for error mitigation and collaborate on development of hardware, software, and protocol solutions, documenting them in the form of QIBA Profiles.

III. Test Solutions: Vendors and researchers implement QIBA solutions to assess their feasibility and efficacy.

**IV.** *Promulgate Solutions:* Validated solutions are disseminated and implemented through vendor adoption, research integration and clinical education.

#### **QIBA Resources**

QIBA meeting summaries, key criteria for identifying biomarker opportunities, the *QIBA Newsletter* and other documents are available on the QIBA website <u>RSNA.ORG/QIBA</u> and wiki <u>http://qibawiki.rsna.org/</u>.

New! QIBA is now on LinkedIn! Follow us at: www.linkedin.com/company/RSNA-QIBA/

# Volunteers for the QIBA Committees are welcome; please contact us at: <a href="mailto:qiba@rsna.org">qiba@rsna.org</a> QIBA Committees

### **QIBA Governance Structure**

QIBA Chair: QIBA Vice Chair:	Edward F. Jackson, PhD Alex Guimaraes, MD, PhD	(University of Wisconsin, School of Medicine & Public Health) (Oregon Health & Science University)
Scientific Liaison: CT:	Andrew J. Buckler, MS	(Elucid Bioimaging, Inc.)
Scientific Liaison: MR:	Thomas L. Chenevert, PhD	(University of Michigan Health System)
Scientific Liaison: NM:	Paul E. Kinahan, PhD	(University of Washington)
Scientific Liaison: US:	Paul L. Carson, PhD	(University of Michigan Health System)

### **Process Committee**

Chair:	Kevin O'Donnell, MASc	(Canon Medical Research USA)
Vice Chair:	Daniel Sullivan, MD	(Duke University Medical Center)

### **Coordinating Committees**

Computed To Co-Chairs: Vice Chair:	mography (CT) Coordinating Committee Rudresh Jarecha, MBBS, DNB, DMRE Lawrence Schwartz, MD David Lynch, MD	(PAREXEL International) (New York Presbyterian Hospital / Columbia University) (National Jewish Health)
Magnetic Res	onance Imaging (MR) Coordinating Comm	ittee
Co-Chairs:	Mark Rosen, MD, PhD	(University of Pennsylvania)
	Gudrun Zahlmann, PhD	(Independent Consultant)
Vice Chair:	Cathy Elsinger, PhD	(NordicNeuroLab, Inc.)
Nuclear Medi	cine (NM) Coordinating Committee	
Co-Chairs:	Richard Wahl, MD	(Mallinckrodt Institute, Washington University)
	Eric Perlman, MD	(Perlman Advisory Group, LLC)
Vice Chair:	P. David Mozley, MD	(Weill Cornell Medical College)
Ultrasound (US) Coordinating Committee		
Chair:	Tim Hall, PhD	(University of Wisconsin, School of Medicine & Public Health)
Vice Chair:	Brian Garra, MD	(Washington DC VA Medical Center / FDA)

### **Biomarker Committees (by imaging modality)**

### <u>CT</u>

### **CT Volumetry**

(PAREXEL International)
(Duke University Medical Center)
(Takeda Pharmaceuticals)

#### Lung Density

**Co-Chairs:** Sean Fain, PhD David Lynch, MD

(University of Wisconsin, School of Medicine & Public Health) (National Jewish Health)

### **Small Lung Nodule**

**Co-Chairs:** Samuel Armato III, PhD David Gierada, MD James Mulshine, MD

# CT Angiography

**Co-Chairs:** Andrew Buckler, MS Luca Saba, MD Uwe Joseph Schoepf, MD... (University of Chicago) (Mallinckrodt Institute of Radiology, Washington University in St. Louis) (Rush University Medical Center)

(Elucid Bioimaging, Inc.) (University of Cagliari (Italy)) (Medical University of South Carolina | MUSC)

### <u>MR</u>

Arterial Spin Labeling (ASL) [Supported by EIBIR] **Co-Chairs** Eric Achten, PhD (University Hospital of Gent, EIBALL) (University College London) Xavier Golay, PhD Matthias Guenther, PhD (Frauenhofer MEVIS) Siegfried Trattnig, MD (Vienna General Hospital / ESR) **Dynamic Contrast-Enhanced (DCE) MRI Co-Chairs** Caroline Chung, MD (University of Texas, MD Anderson Cancer Center) Hendrik Laue, PhD (Fraunhofer MEVIS) Dynamic Susceptibility Contrast (DSC) MRI **Co-Chairs** Bradley Erickson, MD, PhD (Mayo Clinic) Ona Wu, PhD (Massachusetts General Hospital) Diffusion Tensor Imaging (DTI+) **Co-Chairs** Walter Schneider, PhD (University of Pittsburgh) Christopher Whitlow, MD, PhD (Wake Forest University) **Diffusion-Weighted Imaging (DWI) Co-Chairs** Michael Boss, PhD (NIST) Thomas Chenevert, PhD (University of Michigan Health System)

#### fMRI

**Co-Chairs:** Feroze Mohamed, PhD Jay Pillai, MD David Soltysik, PhD

### MRE

**Co-Chairs:** Patricia Cole, PhD, MD Richard Ehman, MD

### MSK

**Co-Chairs** Thomas Link, MD, PhD Xiaojuan Li, PhD

### **Proton Density Fat Fraction**

**Co-Chairs:** Scott Reeder, MD, PhD Takeshi Yokoo, MD, PhD (Thomas Jefferson University Hospital) (Johns Hopkins University) (U.S. Food and Drug Administration (FDA))

(Cole Imaging and Biomarker Consulting, LLC) (Mayo Clinic)

(University of California, San Francisco) (Cleveland Clinic Foundation)

(University of Wisconsin, School of Medicine & Public Health) (University of Texas Southwestern Medical Center)

### <u>NM</u>

FDG-PET Co-Chairs: Rathan Subramaniam, MD, PhD, MPH John J. Sunderland, PhD Scott Wollenweber, PhD

### PET-Amyloid

**Co-chairs:** 

Satoshi Minoshima, MD, PhD Anne Smith, PhD Dawn C. Matthews, MS, MBA

### SPECT I-123

**Co-Chairs:** John Dickson, PhD John Seibyl, MD

### SPECT Tc99m

**Co-Chairs:** Yuni Dewaraja, PhD Robert Miyaoka, PhD (University of Texas, Southwestern Medical Center) (University of Iowa) (GE Healthcare)

(University of Utah) (Siemens Medical Solutions USA, Inc.) (ADM Diagnostics, LLC)

(National Health Service) (Yale University / Institute for Neurodegenerative Disorders)

(University of Michigan Health System) (University of Washington)

### <u>US</u>

#### Contrast Enhanced Ultrasound (CEUS) Co-Chairs:

Michalakis (Mike) A. Averkiou, PhD Richard G. Barr, MD, PhD Todd Erpelding, PhD, MSE

(University of Washington, Seattle) (Northeastern Ohio Medical University) (Canon Medical Systems USA)

Ultrasound Shear Wave Speed Co-Chairs:	
Brian Garra, MD	(Washington DC VA Medical Center / FDA)
Timothy J. Hall, PhD	(University of Wisconsin, School of Medicine & Public Health)
Andy Milkowski, MS	(Siemens Medical Solutions USA, Inc.)
Ultrasound Volume Blood Flow [Su Co-Chairs:	upported by AIUM]
J. Brian Fowlkes, PhD	(University of Michigan Health System)
James Jago, PhD	(Philips Healthcare)
Oliver Kripfgans, PhD	(University of Michigan Health System)

# **QIDW Oversight Committee**

Chair: Bradley J. Erickson, MD, PhD (Mayo Clinic)

# Statistician/Metrology

Nancy Obuchowski, PhD

(Cleveland Clinic)

Updated 27-July-2018